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Abstract
Lymphocytic choriomeningitis virus (LCMV), a natural murine pathogen, is a member of the Arenavirus family, may cause
atypical meningitis in humans, and has been utilized extensively as a model pathogen for the study of virus-induced disease
and immune responses. Historically, viral titers have been quantified by a standard plaque assay, but for non-cytopathic
viruses including LCMV this requires lengthy incubation, so results cannot be obtained rapidly. Additionally, due to specific
technical constraints of the plaque assay including the visual detection format, it has an element of subjectivity along with
limited sensitivity. In this study, we describe the development of a FACS-based assay that utilizes detection of LCMV
nucleoprotein (NP) expression in infected cells to determine viral titers, and that exhibits several advantages over the
standard plaque assay. We show that the LCMV-NP FACS assay is an objective and reproducible detection method that
requires smaller sample volumes, exhibits a ,20-fold increase in sensitivity to and produces results three times faster than
the plaque assay. Importantly, when applied to models of acute and chronic LCMV infection, the LCMV-NP FACS assay
revealed the presence of infectious virus in samples that were determined to be negative by plaque assay. Therefore, this
technique represents an accelerated, enhanced and objective alternative method for detection of infectious LCMV that is
amenable to adaptation for other viral infections as well as high throughput diagnostic platforms.
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Introduction
Lymphocytic choriomeningitis virus (LCMV), an enveloped bi-
segmented RNA virus and natural murine pathogen, is the
prototypic member of Arenaviridae, a family that also includes
human pathogenic viruses such as Lassa, Junin, Machupo and
Whitewater Arroyo that can cause severe viral hemorrhagic fevers
in humans. LCMV infects a wide variety of mammalian cells and
has been extensively studied as a model for acute and chronic viral
disease, virus-specific immunity and host-pathogen interactions in
general [1,2]. Components of the LCM virion that constitute
suitable targets for the quantification of viral infection include the
ambisense RNA genome, surface glycoproteins (GP1 and GP2)
and the viral nucleoprotein (NP), which forms a two dimensional
lattice with the viral RNA inside the viral envelope [2]. The
LCMV-NP, in particular, is an attractive target because NP is
essential for viral propagation and intracellular NP levels increase
during the course of active infection [3,4].
Historically, quantification of LCMV in tissue samples and virus
stocks has been determined using a modified version of plaque
assays originally developed for rubella and poliovirus [5,6,7,8].
Since viral titers are determined by visually counting plaques that
develop as a result of viral destruction of a cell monolayer, this
method requires prolonged incubation of virus with target cells,
especially for non-cytopathic viruses such as LCMV. The
sensitivity of the plaque assay is limited by the surface area of
the tissue culture plates utilized, the large assay volumes utilized
(up to 500 ml) and that often require 100-fold sample dilutions for
analysis, and the ability of the human eye to discern individual
plaques, which in the case of LCMV are particularly heteroge-
neous.
Due to constraints dictated by the extended incubation time
required, observer subjectivity, and limited sensitivity of the plaque
assay, there is a need for more expedient, sensitive methods for
viral detection. Several promising techniques, including Real-
Time RT-PCR for GP and NP transcripts, have been developed
and utilized with some frequency for in vivo and in vitro detection of
LCMV. Quantitation of LCMV RNA is highly reproducible and
sensitive, detecting as few as five RNA copies or the equivalent of
10 PFU/ml of virus [9,10,11]. However, one potential drawback
of quantification of viral titers in tissues and serum by Real-time
RT-PCR is that the number of viral RNA copies present cannot
be directly correlated with infectious virus, particularly in light of
the well-characterized presence of defective interfering virions in
LCMV infection [12,13]. Additionally, the measurement of RNA
copies is not easily comparable with PFU/ml values, which have
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37337been utilized to determine virus titers in most studies performed
over the last 50 years.
Visualization of intracellular LCMV-NP expression by flow
cytometry was originally developed by us and others as a tool to
assess the viral burden among defined primary cell populations
[14,15,16] and various cell lines [17,18,19] following LCMV
infection in vivo and in vitro, respectively. We have now adapted this
methodology to develop a diagnostic approach that accurately
quantifies titers of infectious LCMV, provides both enhanced
sensitivity and expedience, and can be employed effectively as a
surrogate method for analyzing infected tissue samples and viral
stocks routinely measured by the plaque assay.
Results
Optimization of conditions for detection of LCMV-NP
expression by FACS
In order to be useful experimentally and allow for direct
comparison with previous studies, an effective LCMV viral
detection method must produce a determinant of viral titers that
can be directly related to PFU/ml, the standard measure for virus
concentration utilized in the field for more than 50 years. For the
LCMV-NP FACS assay, this was achieved by performing a
dilution series consisting of between 10 and 13 three-fold dilutions
of a 1610
6 PFU/ml LCMV Arm virus stock. The corresponding
percentages of LCMV-NP positive cells were determined by FACS
analysis. Representative histograms illustrating typical LCMV-NP
staining for uninfected, high PFU/ml and mid-range PFU/ml
amounts of LCMV Arm are shown in Figure 1A. Optimal
incubation conditions were determined by varying the length of
exposure of Vero cells to virus within the context of a 48 hour
overall incubation time, which has been demonstrated in previous
experiments (data not shown) to produce a reliable standard curve
for LCMV-NP FACS analysis. All conditions tested resulted in
standard curves with R
2 values of at least 0.97 (Figure 1B).
However, there was a 3-fold increase in sensitivity over the 1 hour
virus exposure when the virus was incubated with Vero cells for
the entire 48 hours (Figure 1B). Incubation of virus for 48 hours
produced similar sensitivity to the 24 hour incubation and resulted
in a 19-fold increase in sensitivity over the plaque assay (Table 1).
Therefore, 48 hour virus exposure was chosen as the standard
assay condition and was utilized for subsequent validation of
LCMV-NP FACS detection with serum samples and organ lysates
from LCMV Clone 13 (cl13) and LCMV Armstrong (Arm)
infected mice.
To determine if the overall assay length could be further
diminished, it was essential to establish the minimum time
required for detection of intracellular NP during in vitro infection
of Vero cells. This was achieved by incubation of the above-
described dilution series of stock virus with Vero cells for 2, 4, 6, 8,
and 24 hours, followed by intracellular detection of LCMV-NP by
FACS. At greater than 1.5610
4 PFU/ml and 3610
2 PFU/ml,
LCMV-NP could be detected in Vero cells at 8 hours and
24 hours, respectively (Figure 2A). However, even at the highest
virus concentration for 24 hour incubation, 100% infection was
not achieved. Therefore, incubation of Vero cells with virus for
more than 24 hours is required to produce a reliable standard
curve that would allow for analysis of unknown samples by
LCMV-NP FACS.
Since incubation of LCMV Arm with Vero cells for 48 hours
resulted in a reproducible standard curve with enhanced sensitivity
over the plaque assay, we tested whether increasing the incubation
time could further increase the sensitivity of the LCMV-NP FACS
assay. To achieve this, Vero cells were incubated with virus for 72,
96, 120, and 144 hours. Exposure of Vero cells to virus for
72 hours resulted in an additional 4-fold increase in assay
sensitivity when compared to 48 hour exposure and a 77-fold
enhancement of sensitivity over the plaque assay (Figure 2B and
Table 1). There was, however, a decrease in the R
2 value of the
curve at 72 hours due to increased variability in replicate points in
the linear range and at lower PFU/ml values. Incubation with
virus for 96, 120, and 144 hours (data not shown) further
enhanced this variability and also produced an all or none
Figure 1. Development and optimization of the LCMV-NP FACS
assay. A 3-fold dilution series of a 1610
6 PFU/ml LCMV Arm virus stock
was produced, incubated with Vero cells, and intracellular LCMV-NP
levels were detected by FACS as described in Methods. (A) 48 hour
virus exposure and FACS detection of LCMV-NP with the unconjugated
antibody and a fluorescently conjugated goat anti-mouse secondary
antibody. Shown are representative histograms for uninfected,
2610
3 PFU/ml and 5610
5 PFU/ml LCMV Arm. (B) Standard curves were
produced from a 3-fold dilution series of LCMV Arm, where virus was
incubated with Vero cells for 1 hour, 24 hours, or 48 hours with a total
incubation time of 48 hours. Virus titers are represented in PFU/ml. All
experiments were performed in duplicate and curves represent
compilation of data for at least 3 individual experiments.
doi:10.1371/journal.pone.0037337.g001
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with virus resulted in 100% LCMV-NP positive cells in all
dilutions containing more than 8 PFU/ml. However, for all
dilutions less than 3 PFU/ml, values were below the limit of
detection (LOD) threshold (less than 2% LCMV-NP positive cells;
data not shown). This abrupt change from complete infection to
no infection in consecutive dilutions is likely due to additional viral
replication and transmission which occurs during the longer
incubation time in vitro, as well as the limiting number of infectious
virions (in relation to defective interfering virions) that are
contained in dilutions with lower PFU/ml values. These results
suggest that an additional 24 hours of incubation (72 hours total)
could be utilized to enhance sensitivity for detection of samples
containing low levels of virus, but that potential assay variability
should be taken into account when utilizing standard curves to
determine experimental values in these instances. Incubation of
virus with Vero cells for more than 72 hours is not recommended
for detection purposes due to increased replicate variability and a
severe decrease in the linear range that can be utilized for
quantification.
Verification of infectious virus detection
In order to ensure that LCMV-NP FACS analysis only detects
infectious virus, 1610
6 PFU/ml LCMV Arm stocks were inacti-
vated by either exposure to 1 Joule of UV irradiation or incubation
at 57uC for 45 minutes. Then, a 3-fold dilution series was
produced, incubated with Vero cells for 48 hours, and intracel-
lular staining of LCMV-NP was assessed. Unmanipulated virus
was run in parallel as a comparative positive control (Figure 3).
UV irradiation completely ablated detection of LCMV-NP, even
at 1610
6 PFU/ml of LCMV Arm, while heat inactivation
reduced the percent of LCMV-NP positive cells at the highest
viral dose by more than 2 fold, but did not completely inactivate
virus, which could be detected in virus concentrations as low as
5610
4 PFU/ml (Figure 3). By plaque assay, the LOD for heat-
inactivated virus was found to be 1610
4 PFU/ml (data not
shown), which was similar to the value determined by LCMV-NP
FACS analysis. These findings confirm our supposition that
LCMV-NP FACS analysis only detects infectious virus and
indicate that effective heat inactivation protocols likely require
extended incubation time or increased temperature to completely
ablate the infectious capacity of LCMV.
Comparative detection limits for plaque and LCMV-NP
FACS assays
The Infectivity Dose 50 (ID50) values, which were derived from
non-linear curve fit analysis and illustrate the PFU/ml value
required to achieve infection in 50 percent of Vero cells, were
found to be 142 PFU/ml and 35 PFU/ml for the 48 hour and
72 hour LCMV-NP FACS assay, respectively. Using the AF647-
conjugated antibody in the 48 hour assay, the ID50 was similar to
the unconjugated antibody at 217 PFU/ml. The ID50 for the
plaque assay was determined to be 2700 PFU/ml (Table 1) using
a 2-fold dilution series of LCMV Arm stock virus (data not shown)
and performing non-linear regression analysis on the values
determined by plaque assay as detailed in Methods. All sensitivity
calculations were determined by comparing the ID50 values for
each assay rather than the lower LOD because the ID50 falls in the
linear range of the assay.
Using the 2-fold LCMV Arm dilution series described above
and determining the highest dilution that yielded at least one
plaque, the LOD for the plaque assay was found to be as low as
Table 1. Detection limits and sensitivity for LCMV-NP FACS
and Plaque assays.
Method ID50 LOD
1 PLOQ
2 Sensitivity
3
144 hr Plaque
Assay
2700 PFU/ml 50 PFU/ml 200 PFU/ml n/a
48 hr FACS Assay 142 PFU/ml 15 PFU/ml 62 PFU/ml 19
72 hr FACS Assay 35 PFU/ml 1 PFU/ml 2 PFU/ml 77
1The limit of detection (LOD) equals +/236the SD of the mean for uninfected
samples.
2The practical limit of quanitification (PLOQ) equals +/2106the SD of the mean
for uninfected samples.
3Values represent fold enhanced sensitivity in comparison to the plaque assay.
doi:10.1371/journal.pone.0037337.t001
Figure 2. Further optimization of the LCMV-NP FACS assay. (A)
The minimum virus exposure time required to detect LCMV-NP was
ascertained by incubating 3-fold serial dilutions of a 1610
6 PFU/ml
LCMV Arm stock with Vero cells for 2, 4, 6, 8, and 24 hours and
subsequent determination of LCMV-NP expression by FACS analysis. (B)
The effect of prolonged incubation of virus with Vero cells on LCMV-NP
FACS assay sensitivity was determined by extending the 48 hour
incubation of 1610
6 PFU/ml LCMV Arm stock serial dilutions by 24 hour
increments; representative curves for 24, 48 and 72 hour incubations
are shown. Virus titers are represented in PFU/ml. All experiments were
performed in duplicate and curves represent compilation of data for at
least 3 individual experiments.
doi:10.1371/journal.pone.0037337.g002
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series of the stock virus described above for LCMV-NP FACS, the
LOD was 50 PFU/ml (Table 1). In practical terms, since there is
often a limited volume of serum samples and organ lysates
available in comparison to the 500 ml volume required for the
plaque assay, 100-fold dilutions are often the lowest utilized.
Under these technical restrictions, the practical LOD is 200 PFU/
ml, which is one plaque in a 1:100 dilution of the sample. Overall,
it is difficult to determine viral titers based on the presence of one
plaque considering the technical nature of the assay and that areas
where cells have detached from the plate often resemble plaques.
The lower detection limits for the LCMV-NP FACS assay using
either the unconjugated and conjugated LCMV-NP antibodies
were calculated as 3 times the standard deviation of the mean for
uninfected samples and were found to be equivalent to PFU/ml
values that resulted in 2 percent and 1 percent LCMV-NP positive
cells, respectively. For the 48 hour LCMV-NP FACS assay with
the unconjugated antibody, the 48 hour LCMV-NP FACS assay
with the conjugated antibody, and the 72 hour LCMV-NP FACS
assay, this value was found to be 15 PFU/ml, 2 PFU/ml, and
1 PFU/ml (Table 1). Since there is still approximately a 1%
probability at this lower limit that resulting values could fall below
the measurements for uninfected samples leading to false
negatives, the practical limit of quantification (PLOQ) for the
LCMV-NP FACS assay was also determined. This was defined as
10 times the standard deviation of the mean for uninfected
samples and corresponded to either 1.5 or 5 percent of LCMV-NP
positive cells, which for the 48 hour LCMV-NP FACS with the
unconjugated antibody was 62 PFU/ml, the 48 hour LCMV-NP
FACS assay with the conjugated antibody was 5 PFU/ml, and the
72 hr FACS assay was 2 PFU/ml (Table 1).
Quantification of viral titers in serum from LCMV cl13
infected mice
In order to ascertain whether detection of LCMV-NP could be
utilized as a suitable replacement for the plaque assay, both
methods were employed in parallel to determine PFU/ml values in
serum samples from C57/BL6 mice infected with 2610
6 PFU
LCMV cl13. For the LCMV-NP FACS assay, dilution series of
individual serum samples were prepared (6 10-fold dilutions
starting at 1:10), a standard curve containing 10 3-fold dilutions of
a1 610
6 PFU/ml stock of LCMV Arm was created at the same
time, and data were generated and analyzed as detailed in
Materials and Methods to calculate individual serum PFU/ml
values. For the plaque assay, serum samples were tested in 3 10-
fold dilutions starting at 1:100, the lowest dilution possible due to
the small volume of serum obtained from blood (,70 ml total for
each mouse). To ascertain the utility of a ‘‘master’’ rather than
individual standard curves, we combined the individual standard
curves generated for the 4, 6, 8, 15, 22, 29, 35, 42, and 56 d.p.i.
experiments (Figure 4A), recalculated the PFU/ml values for
individual samples using this ‘‘master standard curve’’, and found
that virus titers determined using individual or master standard
curves were not significantly different (Figure 4B). Therefore, a
master standard curve produced from a known virus stock can be
utilized to accurately determine viral titers even if the samples are
analyzed on different days, and thus can reduce work load,
reagents and materials.
Importantly, for all time points analyzed, the virus titers
determined by plaque assay or LCMV-NP FACS analysis were
similar (Figure 4B) and serum PFU/ml values for LCMV cl13
infected mice that were determined by either assay were indeed
comparable to previously reported values [20]. For the LCMV-NP
FACS assay, since the values we determined for unknown samples
relate directly to the percentage of LCMV-NP positive cells and
were derived from known PFU/ml values for a particular LCMV
Arm virus stock, we propose to designate them as ‘‘derived PFU/
ml’’. In addition, viral titers for LCMV Arm and LCMV cl13 viral
stocks analyzed by both plaque assay and LCMV-NP FACS
showed no significant differences (data not shown). These results
suggest that analysis of viral titers in both serum samples and viral
stocks by the LCMV-NP FACS assay could be confidently utilized
as an alternative method to the standard plaque assay.
Technical constraints of the LCMV-NP FACS assay and the
use of unconjugated vs. conjugated LCMV-NP antibodies
Analysis of virus in serum and organ samples from infected mice
using the LCMV-NP FACS assay, especially with the unconju-
gated antibody, must take into account a few technical consider-
ations that did not arise when optimization was performed on
LCMV Arm virus stocks. At later stages in the course of LCMV
cl13 infection (.56 d.p.i.), the LCMV-NP FACS analysis of both
serum samples (1:10 dilution) and tissue homogenates produced
high background staining that was also observed in samples
stained only with the fluorescent anti-mouse IgG secondary
antibody (Figure S1A/B, top panels). Since the ‘‘background
staining’’ decreased with each dilution of the serum or tissue lysate
(data not shown) and was not observed in samples obtained early
after infection (Figure S1A/B, middle panels), it conceivably
resulted from the presence of endogenously generated LCMV-
specific antibodies that develop at later time points during the
LCMV cl13 infection [2] or otherwise from the non-specific
binding of the secondary antibody to compounds present in late-
stage sera and organ lysates. In order to overcome these practical
and technical constraints, serum samples and organ lysates from
LCMV cl13 infected mice (98 d.p.i.) were analyzed with the
directly AF647-conjugated LCMV-NP antibody (Figure S1A/B,
bottom panels). Our results not only demonstrated a nearly
complete loss of ‘‘background staining’’ but further indicated that
samples with low viral titers not detectable by standard plaque
Figure 3. LCMV-NP FACS analysis of inactivated virus. A
1610
6 PFU/ml stock of LCMV Arm was inactivated either by exposure
to 1 Joule UV irradiation or by incubation at 57uC for 45 minutes. 3-fold
serial dilutions were produced for inactivated samples as well as
untreated LCMV Arm, incubated with Vero cells for 48 hours, and the
percentage LCMV-NP positive cells was determined. Virus titers are
represented in PFU/ml. All experiments were performed in duplicate
and curves represent compilation of data for at least 3 individual
experiments.
doi:10.1371/journal.pone.0037337.g003
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FACS assay.
Increased sensitivity of the LCMV-NP FACS assay:
practical application to in vivo models of LCMV cl13 and
LCMV Arm infection
In light of the above considerations, we sought to employ the
LCMV-NP FACS assay in experimental scenarios where infec-
tious virus is known to be present at very low levels and not reliably
detectable by standard plaque assay, i.e. in the later stages of an
LCMV cl13 infection (.70 d.p.i.) or during the tail end of a
primary LCMV Arm infection. To this end, we first established
optimal assay conditions for use of the directly AF647-conjugated
LCMV-NP antibody (not shown) and demonstrated that parallel
assays conducted with both unconjugated and conjugated LCMV-
NP antibodies on 8 d.p.i. serum samples obtained from LCMV
cl13 infected mice produced equivalent results (Figure 5A). We
then employed the conjugated LCMV-NP antibody to determine
viral titers in 98 d.p.i. serum samples and organ lysates from
LCMV cl13 infected mice (Figure 5B). Previous studies using the
standard plaque assay demonstrated effective clearance of LCMV
cl13 from multiple tissues including serum, spleen, and liver by
70–80 d.p.i. but maintenance of elevated LCMV titers in brain
and kidney [20]. Our own plaque assay-based quantification of
Figure 4. Detection of viral titers in sera of LCMV cl13 infected mice: comparison of LCMV-NP FACS and plaque assays. (A) A master
standard curve was produced by combining 9 individual standard curves generated for separate experiments by incubation of 10 3-fold serial
dilutions of the 1610
6 PFU/ml LCMV-Arm virus stock with Vero cells for 48 hours and subsequent determination of LCMV-NP expression by FACS. (B)
C57/BL6 mice were infected i.v. with 2610
6 PFU LCMV cl13, serum samples were collected on 4, 6, 8, 15, 22, 35, 42 and 56 d.p.i., and viral titers were
determined by both the LCMV-NP FACS assay (‘‘derived PFU/ml’’) and standard plaque assay (PFU/ml). ‘‘Derived PFU/ml’’ values were calculated with
individual standard curves generated at the time of experiment (closed symbols) or the above master standard curve (open symbols) generated after
completion of all experiments. The symbols represent 5 individual mice for 4, 6, 8 d.p.i. and 4 mice for 15, 22, 29, 35, 42 and 56 d.p.i.
doi:10.1371/journal.pone.0037337.g004
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mice at 98 d.p.i. confirmed these observations by demonstrating
absence of detectable virus in serum, spleen and liver as well as
virus persistence in kidney (5/5 mice) and brain (2/5 mice)
(Figure 5B). In a direct comparison, the LCMV-NP FACS
yielded identical results for liver, spleen, brain and kidney
(Figure 5B). In fact, the brain lysates that tested positive for virus
by both plaque assay and LCMV-NP FACS were from the same
individual mice (data not shown). These results further confirm
that detection by LCMV-NP by flow cytometry can be used as a
surrogate method for the plaque assay. Interestingly, we noted
detection of infectious virus in a serum sample from one mouse
that was deemed negative by plaque assay (Figure 5B), suggesting
that the LCMV-NP FACS assay might provide information about
infection and viral persistence that is beyond the reach of the
standard plaque assay.
To explore the possibility for enhanced detection of infectious
virus by means of the LCMV-NP FACS assay, we quantified virus
titers in the course of a primary LCMV Arm infection (Figure 5C),
a model of acute viral infection and disease that is associated with
early, brief and mostly lower spikes of LCMV titers [20]. Since
LCMV Arm is cleared from most tissues by 8 d.p.i. [20],
endogenously generated LCMV-specific antibodies would not be
expected to interfere significantly with the use of the 2-step
LCMV-NP assay, an approach that can provide certain advan-
tages due to its capacity for signal amplification. In 2, 4, 6, 8 d.p.i
serum samples from LCMV-arm infected mice, analysis by
LCMV-NP FACS using the unconjugated LCMV-NP antibody,
for all time points, except 4 d.p.i, resulted in detection of virus in
samples from mice that were determined to be negative by plaque
assay (Figure 5C, left panel). In only one instance was there
detection of virus in a sample (from 4 d.p.i. serum) by plaque assay
that was determined to be negative by LCMV-NP FACS. It
should be noted, however, that analysis of the very same sample
with the AF647-conjugated LCMV-NP antibody readily permitted
detection of virus (described below and in Figure 5C, right panel).
Our results demonstrate that LCMV-NP FACS, using either the
conjugated or unconjugated antibody, can detect virus where the
standard plaque assay could not, and therefore provides simple
analytical methodology for improved quantification of infectious
LCMV titers.
When extending the above analyses to various tissues from
LCMV Arm infected mice, however, we encountered technical
difficulties similar to those described above for the use of
unconjugated LCMV-NP antibody with organ lysates obtained
from LCMV cl13 infected mice, and which we attribute mostly to
background caused by non-specific binding to the large amount of
protein and other macromolecules in the tissue homogenates.
Again, analysis of both serum and organ lysates by use of the
AF647-conjugated LCMV-NP antibody eliminated confounding
background staining and allowed for detection of virus in organ
lysates prepared from LCMV Arm infected mice at 8 d.p.i.
(Figure 5C, right panel). In particular, the FACS assay led to
detection of virus in spleen and brain lysates that were negative by
plaque assay. However, liver and kidney lysates were negative for
virus using either method. Viral titers in sera on 4 and 8 d.p.i.
determined by the plaque assay and LCMV-NP FACS were
nearly identical (Figure 5C, right panel) and similar to that
determined by LCMV-NP FACS using the unconjugated
antibody (Figure 5C, left panel). The main limitation of both
LCMV-NP FACS and the plaque assay in detecting extremely low
levels of virus is the requirement for dilution of serum and organ
lysates for analysis and may explain why there is not detection of
virus in more samples by LCMV-NP FACS, even with 19-fold
increased sensitivity. Another possibility is that these samples
simply do not contain infectious virus. Overall, our findings
demonstrate that detection of virus by LCMV-NP FACS,
especially using the conjugated antibody to avoid background
due to non-specific binding or the presence of endogenous
LCMV-specific antibodies, constitutes a simple, fast and accurate
methodology for the quantification of infectious LCMV across a
wide range of viral titers including low amounts of virus that
cannot be detected by standard plaque assay.
Discussion
Recently, several studies illustrating improved methods for
detecting LCMV, especially real time RT-PCR for viral RNA,
have been reported [9,10,11]. It has been shown that RNA
detection is a rapid, sensitive method for identifying LCMV viral
presence in murine tissues and clinical samples, which has several
advantages over the standard plaque assay (Table 2). There are
several factors that limit the value of RNA analysis for viral
quantification in research as opposed to clinical usage. Quantifi-
cation is generally expressed in RNA copies and only one study
[11] represented RNA copies and LOD values in terms of PFU/
ml, the standard experimental measure for LCMV and most other
infections. Additionally, especially for lower limits of detection, the
presence of viral RNA does not necessarily correlate with active
viral infection. Real-time RT-PCR is also less cost effective than
plaque or FACS-based assays (Table 2). Therefore a more
sensitive, quicker detection assay that can be used as a surrogate
for the plaque assay in detecting infectious virus has many
practical and technical advantages over RNA detection for
everyday experimental use.
In this study, we describe the development and optimization of
a FACS-based assay for quantification of LCMV viral titers which
provides several advantages over the commonly utilized plaque
assay. These include enhanced sensitivity, decreased assay length,
reduced sample volume due to usage of the 96-well plate format,
and improved sample processing (8–12 duplicate samples per
plate). The 96-well plate format also provides a convenient
foundation for high throughput flow cytometry using a variety of
fully automated and integrated acquisition and analysis platforms.
Overall, assay conditions optimized for a length of 48 hours
demonstrated an up to 19-fold enhancement in sensitivity over the
standard plaque assay and an increase of incubation time to
72 hours improved the assay sensitivity by a factor of ,80 in
comparison to the 6 day plaque assay. Our application of this
methodology to models of acute (LCMV Arm) and chronic
(LCMV cl13) viral infection produced comparable results in
relation to the standard plaque assay and, under experimental
conditions associated with limiting amounts of infectious LCMV,
permitted improved virus detection due to enhanced assay
sensitivity. Potential drawbacks of the LCMV-NP FACS assay
include enhanced sample processing time as compared to the
plaque assay as well as the requirement to perform somewhat
extended dilution series (usually 4–6 dilutions) to assure that the
experimental readout (% LCMV-NP positive cells) falls within the
linear range of the corresponding standard curve, a critical
condition to permit the accurate calculation of PFU/ml values. In
situations where results are not needed immediately, only a
general estimate of the virus titer is necessary, or the titer of new
viral stocks is being measured, the traditional plaque assay might
therefore be a more practical option. However, since the exact
quantification of LCMV titers often constitutes a critical exper-
imental readout [16], the LCMV-NP FACS assay can provide a
faster, more sensitive and accurate methodological alternative in a
Quantification of LCMV Titers by FACS
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this assay can, in principle, be adapted to other viruses and model
systems (eg, influenza) where rapid, objective, enhanced and
accurate quantification of virus titers is of diagnostic importance.
Materials and Methods
LCMV-NP antibody production and fluorescent
conjugation
The primary mouse IgG2a antibody specific for the LCMV-NP
was produced from the M-Se 113 Hybridoma (generously
provided by Dr. M. Oldstone) and was purified by the University
Figure 5. Detection of infectious LCMV under experimental conditions with limited virus titers: comparison of 1-step and 2-step
LCMV-NP FACS and plaque assays. (A) For validation of the AF647-conjugated LCMV-NP antibody, serum titers of LCMV cl13 infected mice (d.p.i)
were analyzed by LCMV-NP FACS using both conjugated and unconjugated versions of the antibody; viral titers are represented in ‘‘derived PFU/ml’’.
(B) C57/BL6 mice were infected i.v. with 2610
6 PFU LCMV cl13, serum samples were collected and organ lysates prepared at 98 d.p.i., and viral titers
were determined in parallel by LCMV-NP FACS using the AF647-conjugated LCMV-NP and standard plaque assay. Virus titers are represented in
‘‘derived PFU/ml’’ (FACS assay) or PFU/ml (plaque assay). (C) C57/BL6 mice were infected i.p. with 2610
5 PFU of LCMV Arm, serum samples were
collected on 2, 4, 6, 8 d.p.i and organ lysates from kidney, spleen, liver and brain were produced on 8 d.p.i. Viral titers were determined for serum 2, 4,
6, 8 d.p.i. by both the LCMV-NP FACS using unconjugated anti-LCMV-NP, and standard plaque assay (left panel). Viral titers were determined on 4 and
8 d.p.i. in serum and in kidney, spleen, liver, and brain from 8 d.p.i. by both the LCMV-NP FACS using the AF647-conjugated anti-LCMV-NP and the
standard plaque assay (right panel). Viral titers are represented as in panel B.
doi:10.1371/journal.pone.0037337.g005
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ized protocols. In brief, the hybridoma was seeded at a low
density of 5.0610
5 cells/ml in RPMI with 7% fetal calf serum
(FCS), 1% penicillin, 1% streptomycin, and 1% L-glutamine, and
expanded in spinner vessels (BellCo Glass, Vineland, NJ) for 7
days until growth reached the log phase. The supernatant was
harvested and run twice over a 1 ml Hi-Trap Protein G Column
(GE Healthcare, Piscataway, NJ), washed with PBS, and eluted
using a low pH elution glycine buffer (Perkin-Elmer, Waltham,
MA). The elutant was dialyzed two times in 1 L of PBS for
3 hours, then analyzed for purity and protein concentration by
Coomassie Blue Gel (Bio-Rad, Hercules, CA). The purified
antibody was stored at 2 mg/ml in 500 mla l i q u o t sa t220uC
until use for FACS detection utilizing a Cy5-, DyLight 649- or
Alexa Fluor 647 (AF647)-conjugated goat anti-mouse IgG F(ab9)2
fragment as a secondary antibody (Jackson Immunoresearch
Laboratories, Inc., West Grove, PA). Functional activity and
optimal antibody concentration for detection of LCMV were
determined by FACS analysis using Vero cells infected with
1.0610
6 PFU/ml LCMV Armstrong (Arm) for 1 hour followed
by media change and additional 48 hours of incubation at 37uC,
5% CO2 as described [19]. Uninfected cells stained with both
primary and secondary antibodies and virus-infected cells stained
with the secondary antibody alone were utilized as negative
controls. Alternately, the LCMV-NP antibody was fluorescently
conjugated using an AF647 Protein Labeling Kit (Molecular
Probes, Carlsbad, CA).
Virus production, storage and inactivation
The LCMV Armstrong (Arm) and LCMV clone 13 (cl13)
strains [21] utilized in all experiments were originally obtained
from Dr. M. Oldstone, and stocks were produced as described
previously [22]. Viral titers for stock virus were determined using
the standard plaque assay (described below). Long-term LCMV
Arm and cl13 stocks utilized for infections were stored in 1 ml
aliquots in liquid nitrogen and thawed immediately before use.
Working stocks for LCMV Arm utilized for the standard curve
and assay optimization were diluted from liquid nitrogen stocks to
1610
6 PFU/ml and stored in 1 ml aliquots at 280uC until use.
LCMV Arm was inactivated using both heat and UV techniques
following previously published methods [23,24]. For UV inacti-
vation, 1610
6 PFU/ml stocks of LCMV Arm were subjected to 1
Joule/cm
2 of UV irradiation in a Spectrolinker XL-1500 UV
cross-linker (Spectronics Corporation, Westbury, NY). Heat
inactivation was achieved by incubating 1610
6 PFU/ml stocks
of LCMV Arm in a 57uC water bath for 45 minutes. All
inactivation procedures were performed immediately prior to
addition of virus to Vero cells.
LCMV plaque assay
LCMV plaque assays were performed as described previously
[25,26]. Vero cells (originally obtained from Dr. M. Oldstone [26])
were re-suspended in MEM media containing 7% FCS, 1%
penicillin, 1% streptomycin, and 1% L-glutamine, plated in 6 well
tissue culture plates at 1610
5 cells/ml and incubated overnight at
37uC and 5% CO2. Vero cells were then incubated with 2-fold
dilutions of a 1610
6 PFU/ml LCMV Arm virus stock (for
determination of assay sensitivity) or 10-fold dilutions of serum
samples and organ lysates in a total volume of 500 ml for 1 hour at
37uC and 5% CO2. The supernatant was aspirated and replaced
with an overlay consisting of a 1:1 mixture of 1% agarose and
EMEM medium containing 14% FCS, 2% L-glutamine, 2%
penicillin, and 2% streptomycin. The plates were then incubated
at 37uC and 5% CO2 for 6 days. On day 6, the agarose overlay
was removed, cells were fixed in 25% formalin for 45 minutes, and
stained with 16 crystal violet (Sigma, St. Louis, MO). Plaques
were visually counted and PFU/ml values were determined using
the following formula: # of plaques per well 62/dilution factor.
LCMV-NP FACS assay
FACS detection of LCMV-NP was modified from previously
described protocols [14,15,19,27]. Vero cells were plated in flat
bottom 96-well tissue culture plates in MEM media at 5610
4 cells
per well and incubated at 37uC and 5% CO2 overnight. Serial
dilutions of the 1610
6 PFU/ml LCMV Arm viral stock (11 to 14
duplicate 3-fold dilutions) were prepared in MEM media and
50 ml of each dilution was added to Vero cells. To avoid variation
in detection that could occur as a result of evaporation during
longer incubations, an additional 50 ml of MEM media was added
to each well for a final volume of 100 ml and Vero cells were
incubated with virus for the indicated time period for each
individual experiment. Cells were then washed with cold 16PBS
and incubated with 60 ml of warm 0.25% Trypsin-EDTA (Gibco,
Carlsbad, CA) at 37uC for 5 minutes. 60 ml of cold MEM media
with 7% FCS was then added to each well, the cells were removed
by gentle pipetting, and transferred to a 96-well V-bottom plate.
Cells were pelleted by centrifugation at 1600 rpm, re-suspended in
PFA with 1% saponin, and incubated at room temperature for
15 minutes. The cells were pelleted by centrifugation at 1600 rpm
and washed twice in PBS with 1% saponin. The cells were then re-
suspended in PBS with 1% saponin containing 4 mg/ml of the
primary LCMV-NP mouse IgG2a or 9.75 mg/ml of the AF647-
conjugated LCMV-NP antibody and incubated at room temper-
ature for 40 minutes. The cells were pelleted by centrifugation at
1600 rpm and washed twice in PBS with 1% saponin. Next, the
cells were re-suspended in PBS with 1% saponin containing 5 mg/
ml of Cy5-, DyLight 649- or AF647-conjugated goat anti-mouse
F(ab9)2 (Jackson Immunoresearch Laboratories, Inc., West Grove,
PA) and incubated at room temperature for 30 minutes (for the
directly conjugated antibody, this step was omitted). The cells were
Table 2. Comparison of detection methods for LCMV viral titers.
Method Duration Objectivity LOD
1 Infectious Virus? Cost
Plaque Assay 6 days + 50 PFU/ml + $
48 hr FACS Assay 2 days ++ 15 PFU/ml + $$
72 hr FACS Assay 3 days ++ 1 PFU/ml + $$
RT-PCR Assay 4–5 hours ++ 10 PFU/ml 2 $$$
1The limit of detection (LOD) equals +/236the SD of the mean for uninfected samples.
doi:10.1371/journal.pone.0037337.t002
Quantification of LCMV Titers by FACS
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37337then washed twice in PBS with 1% saponin, re-suspended in
FACS buffer (PBS, 1% FCS and 0.5% sodium azide), and
analyzed on the FACSCalibur Flow Cytometer (BD Biosciences,
Franklin Lakes, NJ). Virus positive populations were determined
by negatively gating on uninfected samples. Gates were adjusted to
account for fluctuations in fluorescent background (compared to
samples stained with the fluorescent secondary antibody only as a
negative control) and variations in fluorescent intensity of negative
populations, especially for serum samples and organ lysates from
infected mice (see below).
Mice, infections and quantification of viral titers in serum
and organs
Male C57/BL6 mice were infected intravenously (i.v.) with
2610
6 PFU LCMV cl13 or intraperitoneally (i.p.) with
2610
5 PFU LCMV Arm, blood was collected at various days
post infection (d.p.i.) as indicated in Figures 4, 5 and S1, and
serum was obtained by centrifugation at 8000 rpm for 5 minutes
at 4uC. For determination of LCMV titers in solid tissues (spleen,
liver, brain, kidney; Figures 5 and S1), harvested organs were
weighed, a weight-adjusted volume of MEM media with 7% FCS
was added to each tissue, and organ lysates effectively corre-
sponding to a 1:10 dilution were produced by grinding the organs
with a tissue homogenizer. Serum and organ homogenates were
diluted in 10-fold increments and 2-day LCMV-NP FACS and 6-
day standard plaque assays were performed in parallel as described
above. For the LCMV-NP FACS assay, a standard curve was
produced using 3-fold dilutions of a 1610
6 PFU/ml LCMV Arm
stock, and ‘‘derived PFU/ml’’ values for serum samples were
interpolated from the standard curve by non-linear regression
analysis using Prism 5.0 software (GraphPad Software, Inc., San
Diego, CA). Since the accurate derivation of PFU values is
contingent on experimental readouts above detection limits (i.e.
.2% LCMV-NP positive Vero cells) and ideally within the linear
range of the standard curve, it is important to consider the exact
number of dilutions to be analyzed: in general, the higher the
expected virus titers, the more dilutions should be prepared, and in
most cases 4–6 10-fold dilutions were sufficient to meet the above
criteria (thus permitting the duplicate analysis of 8–12 samples per
96-well plate). For samples with expectedly lower virus titers, we
recommend tighter-spaced dilution series (1:3 to 1:5). For
representative dot plots of dilutions containing low levels of virus
that scored positive and negative, respectively, see Figure S1A/B,
bottom panels. All procedures were performed in accordance with
NIH guidelines, were approved by the University of Colorado
Institutional Animal Care and Use Committee (#B-70210(05)1E),
and all efforts were made to minimize suffering of animals.
Statistical analysis and calculation of FACS and plaque
assay sensitivity
Statistical analysis was conducted using the Prism 5.0 statistical
program (GraphPad Software, Inc., La Jolla, CA). All standard
curves were generated and unknown serum and tissue values were
interpolated using non-linear curve fit analysis; ‘‘derived PFU/ml’’
corresponding to infection of 50% of Vero cells were designated as
the infectivity dose 50 (ID50). For the plaque assay, the ID50 was
determined by non-linear regression analysis from a 2-fold dilution
series using the same 1610
6 PFU/ml LCMV Arm stock utilized to
generate curves for the LCMV-NP FACS assay. Differences in the
ID50 values were employed to determine the fold-enhanced
sensitivity in comparison to the plaque assay displayed in Table 1.
The limit of detection (LOD) and practical limit of quantitation
(PLOQ) for the LCMV-NP FACS assay using the unconjugated
and conjugated antibodies were determined as plus or minus 3 and
10 SD of the mean of ‘‘LCMV-NP
+’’ cells in uninfected replicates
(n.50 and n=4, respectively).
Supporting Information
Figure S1 Technical considerations for detection of
virus in serum samples and organ lysates using
LCMV-NP FACS. (A) Representative dot plots generated by
LCMV-NP FACS analysis of serum samples obtained from
LCMV cl13 infected mice 70 d.p.i. (top panel), 8 d.p.i. (middle
panel) and 98 d.p.i (bottom panel). Note the enhanced ‘‘back-
ground staining’’ of the 2-step procedure (top panel, compare
‘‘aLCMV-NP’’ +IIu and ‘‘IIu only’’) and the reduction thereof
using the directly conjugated LCMV-NP antibody (bottom panel,
‘‘aLCMV-NP-AF647’’). (B) Representative dot plots of LCMV-
NP FACS analyses conducted with 1:30 dilutions of liver lysates
from LCMV cl13 infected mice (top panel: 107 d.p.i., middle
panel: 8 d.p.i. and bottom panel: 98 d.p.i.). As above, note the
background in the 2-step (top) but not 1-step (bottom) staining
procedure.
(TIF)
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